Interactions between ER and GFR signaling such as IGF1R, HER2, and FGFR have been described, suggesting an additional therapeutic strategy to block ESR1 mutant-driven BC by targeting non-genomic signaling pathways (25, 35, 87–90). Here, IGF1R is linked to breast cancer.